The FDA has warned consumers about risks including dosing errors and concerns about certain salt forms and products from non-verified sellers
In certain clinical scenarios, the medical providers may determine that a carefully monitored extension beyond the standard 12-week period is appropriate
You should expect noticeable appetite reduction within the first 12 weeks, with meaningful weight loss appearing over 48 weeks at therapeutic doses
Although diabetes and obesity have been become increasingly prevalent, new developments are giving patients options and changing the way diabetes can be treated
In the landmark Phase 3 VESALIUS-CV trial (12,000+ patients), adding Repatha to standard cholesterol-lowering therapy significantly reduced the risk of: Heart attacks Ischemic strokes Coronary deaths This makes Repatha the first PCSK9 inhibitor to demonstrate preventive benefits before heart disease strikes a true paradigm shift in cardiovascular care
Our new IV Therapy offers a quick and effective way to boost health and vitality by delivering essential nutrients directly into the bloodstream for maximum absorption
